Why TEER (MitraClip) Is Changing Mitral Valve Treatment for High-Risk Patients

In modern cardiology, few innovations have offered as profound a reprieve as the
mitral clip. It addresses a historically heartbreaking scenario: patients suffering from
a severely leaking valve who are deemed far too high-risk for traditional operative
repair.

Where we once had no choice but to rely on medical management to cushion a
gradual decline, transcatheter edge-to-edge repair now offers a definitive, minimally
invasive lifeline. With over 200,000 procedures completed globally, TEER stands on
an exceptionally strong foundation of clinical evidence. Having spearheaded India’s
inaugural percutaneous mitral valve repair, I have seen firsthand how this field
transitioned from an experimental frontier into an essential mainstay. For patients
whose bodies cannot endure open surgery, the data behind this approach changes
everything.

What Is TEER, and What Is the MitraClip?

Transcatheter edge-to-edge repair, or TEER, is a way of mending a leaking mitral
valve without surgery. Its principle is borrowed directly from the operating theatre. In
the 1990s, an Italian surgeon named Ottavio Alfieri devised a repair in which the two
leaflets of a leaking mitral valve were stitched together at their midpoint, converting
one large leaking opening into two smaller ones that sealed far better. The MitraClip,
and the newer devices that have followed it, achieve exactly this from inside the
heart, using a tiny clip delivered through a vein in place of a surgeon’s stitch. The
valve is repaired, not replaced, using the patient’s own tissue, and the leak is reduced
at the very point where the leaflets fail to meet.

How the Procedure Works

There is a profound craftsmanship to transcatheter repair. Operating from within the
vascular system, we enter through the femoral vein in the leg and thread our
micro-instruments up into the heart’s upper chambers. Guided by live 3D ultrasound which projects a real-time, high-definition map of the
valve’s dynamic movement, we navigate the clip directly to the point of structural
failure. As we draw the leaking edges of the valve leaflets into place, the regurgitation
disappears before our eyes in the control room. Whether it takes one clip or two, the
entire approach is engineered to minimize physical strain. The patient remains under
light, comfortable sedation, recovers rapidly, and typically transitions from hospital to
home in just a couple of days.

The High-Risk Patients TEER Was Made For

Transcatheter edge-to-edge repair (TEER) was designed to solve one of
cardiology’s toughest challenges: treating a severely leaking mitral valve in patients
who are too fragile for an operation.

Clinical candidates generally belong to two key categories. The first includes
individuals with primary mitral regurgitation, a structural defect in the valve itself,
who carry prohibitively high surgical risk due to frail health, age, or previous chest
surgeries. The second group, where the clinical trial evidence is most compelling,
includes patients navigating advanced heart failure. In these cases, the valve leak is
secondary: the heart chamber has dilated so significantly that even a healthy valve
can no longer meet in the middle to seal.

When open surgery poses a severe threat to a patient’s survival, non-surgical mitral
valve repair offers a life-saving alternative, repairing the heart from within without
ever opening the chest.

What the Evidence Shows

Clinical data for transcatheter edge-to-edge repair (TEER) is unusually definitive,
though its application varies by the type of regurgitation being treated. For primary
valve defects, early landmark studies like EVEREST II confirmed that catheter-based
repair offered superior safety compared to invasive surgery. However, the paradigm
shifted completely in 2018 with the publication of the COAPT trial for secondary
heart failure-induced valve leaks. Adding a mitral clip to gold-standard medical
therapy achieved a dramatic 47% reduction in heart failure hospitalizations and
cut two-year mortality rates by 38%, a profound survival advantage that has held firm
at five-year follow-ups. Understanding why TEER succeeds requires comparing
COAPT with the contemporaneous French MITRA-FR study, which found no
significant difference. The key takeaway is clinical discernment: COAPT selected
patients with disproportionately severe leaks who stood to gain maximum structural benefit from repair, while MITRA-FR included end-stage hearts where the muscle
damage was simply too far advanced. This trial contrast proved that MitraClip
procedure success relies heavily on rigorous candidate selection.

Reaffirmed by recent findings from the MATTERHORN trial, which proved TEER to
be just as effective as traditional surgery in specific heart failure cohorts,
catheter-based valve repair has firmly established itself as an indispensable tool in
modern interventional cardiology.

Why This Is Genuinely Changing Mitral Care

The compelling clinical trial data behind transcatheter edge-to-edge repair (TEER)
has fundamentally shifted how we approach complex structural heart care.
International cardiology guidelines now grant the MitraClip procedure their highest
recommendation level for selected heart failure patients suffering from secondary
mitral regurgitation, a high-risk group that previously had few options beyond
symptom-managing medications.

With additional advanced clip devices gaining regulatory approval, interventional
cardiologists now have expanded choices to customize treatment, driving the global
number of successfully treated patients well past 200,000. For the individual patient,
this shift is life-changing. Individuals once told that their leaking mitral valve was
inoperable, and that they must endure chronic breathlessness and recurrent
hospitalizations, can now undergo a minimally invasive valve repair. This therapy
not only restores quality of life and reduces hospital admissions, but actively extends
survival. It represents one of the most meaningful clinical breakthroughs in my
career.

An Honest Word on the Limits

True clinical expertise lies in knowing exactly when not to use a piece of technology.
While the MitraClip procedure is a revolutionary tool, it is not a universal solution. If a
young, fit patient comes to me with primary mitral regurgitation, surgical repair still
delivers the most comprehensive and lasting outcome, and surgery is exactly what I
will recommend.

The clinical reality of transcatheter edge-to-edge repair (TEER) is that it
aggressively reduces valve leakage, but it does not guarantee total elimination.
Because a residual leak can impact long-term health, success relies absolutely on
choosing the correct candidate and executing the placement flawlessly. This level of
exactness demands advanced 3D imaging, deep operator experience, and the
collaborative insight of a dedicated Heart Team. Ultimately, the wisdom behind the
decision is just as critical as the hands performing the procedure.

TEER and the Mitral Valve in India

The clinical impact of advanced catheter-based valve repair is nowhere more
urgent than in India. Our country faces a dual challenge: a massive historical burden
of rheumatic valve damage among younger cohorts, and a rapidly growing
population of seniors suffering from heart failure-induced valve leaks.

Since leading India’s inaugural minimally invasive mitral valve repair, my mission
has been to ensure our patients have direct access to global innovations. Today,
Indian interventional cardiology stands at the absolute forefront of structural heart
care. With state-of-the-art imaging, international-standard devices, and dedicated
multidisciplinary teams, high-risk patients with a leaking mitral valve can receive
life-saving, evidence-based therapy right here in India, delivered with
uncompromised precision and care.

Frequently Asked Questions

Is the MitraClip safe for elderly patients?

Yes. The procedure was designed precisely for older and frailer patients who could
not survive an operation, and some of the most rewarding results I have seen have
been in patients in their eighties and nineties. Serious complications are uncommon,
and a heart team assesses each patient carefully beforehand. Age alone rarely rules
anyone out.

How long is recovery after TEER?

Recovery is quick, because there is no chest wound to heal. Most patients are
walking within a day, home within two or three days, and back to their ordinary
activities within a couple of weeks, far sooner than the six to twelve weeks that open
mitral surgery usually demands.

Is TEER as good as mitral valve surgery?

It depends on the patient. For someone fit for surgery with a primary, degenerative
leak, an operation gives a more complete and more durable repair. For high-risk
patients, and for heart-failure patients with a secondary leak, TEER is often the better
choice.